Investment bank Goldman Sachs has raised $650 million to invest in privately held startups in the biotech sector. The company has closed its first-ever life sciences fund, called West Street Life Sciences I. The fund will be used to invest in genetic medicine, cell therapies, immunotherapies, synthetic biology, artificial intelligence startups, as well as diagnostics and life science tools companies. First-time funds have been difficult to raise during the biotech downturn, with the lowest fundraising total for first-timers since 2013 recorded in 2023. Around $11.6 billion was raised by 183 new VC funds last year, compared to $25.6 billion raised by 556 first-time funds in 2022.
Goldman Sachs rockets with huge $650M fund for life science!
Latest from Blog
VCFA Group Closes $1225M Venture Partners VII Fund
TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in
VCFA Group’s Venture Partners VII Fund Raises $1225 Million
TLDR: VCFA Group closed its latest fund, VCFA Venture Partners VII, with $122.5 million in commitments. The fund focuses on smaller and more complex purchases of later-stage venture capital and growth equity
Revolutionizing Payments: $20M Raised for Stablecoin Network Development
TLDR: 1Money has raised over $20 million in seed funding to develop a stablecoin payments network. The network aims to offer instant transaction confirmation, low-cost fees, multicurrency support, compliance mechanisms, and scalability.
Top AI Trends and Startups Shaping 2025 and Beyond
“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI
Sand Hill Road: Steve Vassallo’s Early Investment Edge at Foundation Capital
“`html TLDR: Steve Vassallo, a general partner at Foundation Capital, focuses on early-stage investments, often being the first institutional investor for startups. He emphasizes the importance of owning a significant stake in